Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator

Rezatapopt is a clinical-stage compound that offers a promising treatment option for TP53-mutant cancers. This study details the characterization of rezatapopt and its related compounds, which can reinstate the tumor suppressor activity of the p53 Y220C mutant. These results emphasize the potential for targeting p53 mutations in cancer therapy.

Authors

Institutions

Publication Details

Journal
Cancer Discovery
Published
2025-02-13
DOI
https://doi.org/10.1158/2159-8290.cd-24-1421
Citations
33
Primary Topic
Cancer-related Molecular Pathways
Type
article
Field-Weighted Citation Impact
34.50

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator

Kimberly A. Robell, Jonathan D. Oliner, Brandon M. Russo, Masha V. Poyurovsky et al.
33 citations
Cancer Discovery
Cancer-related Molecular Pathways
34.50
article

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator

Kimberly A. Robell, Jonathan D. Oliner, Brandon M. Russo, Masha V. Poyurovsky, Shunbin Xiong, Melissa L. Johnson, Anna M. Puzio‐Kuter, Hongju H. Li, Mary Kate McBrayer, Bruce J. Fahr, Dafydd H. Thomas, Romyr Dominique, Benjamin D. Greenbaum, Josh Battaglia, Kuo‐Sen Huang, Guillermina Lozano, Binh T. Vu, Alison M. Schram, Melissa Dumble, Alyssa M. Brown, Arnold J. Levine, Amy E. Wiebesiek, Hong Yang, Peirong Yang, Marc Fellous, Lizhong Xu, Chris L. Mulligan, Thomas W. Davis, Alexander Solovyov
article en
33 citations

Abstract

Rezatapopt is a clinical-stage compound that offers a promising treatment option for TP53-mutant cancers. This study details the characterization of rezatapopt and its related compounds, which can reinstate the tumor suppressor activity of the p53 Y220C mutant. These results emphasize the potential for targeting p53 mutations in cancer therapy.

Cancer DiscoveryVol. 15(6)
Amgen (United States) (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Princeton University (US), Kettering University (US), Institute for Advanced Study (US), Sarah Cannon (US), Nutrasource (CA), Tennessee Oncology (US)
National Cancer Institute
Life in Land
Openalex Percentile: Top 0%
Cancer-related Molecular Pathways
34.50
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.